Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | DCLRE1A | Q6PJP8 | 1/20 | 0.35 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL125429 | 0.85 | IDO1 (0.63) | IDO1APOBEC3GTSHRHSPA5TAAR1 | |
| SCHEMBL29366632 | 0.85 | APOBEC3G (0.60) | APOBEC3GPDCD1CD274TSHRCYP4F2 | |
| SCHEMBL29365799 | 0.85 | IDO1 (0.63) | IDO1APOBEC3GTSHRHSPA5TAAR1 | |
| SCHEMBL41139 | 0.85 | APOBEC3G (0.60) | APOBEC3GPDCD1CD274TSHRCYP4F2 | |
| Hydrochloric Acid SCHEMBL28375849 | 0.79 | APOBEC3G (0.55) | IDO1APOBEC3GPDCD1CD274TSHR | |
| SCHEMBL16710798 | 0.79 | IDO1 (0.46) | IDO1APOBEC3GCYP4F2CYP4A11HSPA5 | |
| SCHEMBL2651606 | 0.77 | IDO1 (0.39) | IDO1APOBEC3GPDCD1CD274TSHR | |
| SCHEMBL3289222 | 0.77 | HSPA5 (0.52) | APOBEC3GPDCD1CD274TSHRCYP4F2 | |
| SCHEMBL6244844 | 0.74 | TSHR (0.63) | APOBEC3GPDCD1CD274TSHRCYP4F2 | |
| SCHEMBL2642525 | 0.72 | APOBEC3G (0.48) | IDO1APOBEC3GPDCD1CD274TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11090316-B2 | Lipid disulfide prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| US-20200306272-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2020-10-01 | — | — | US | disclosed |
| CN-107531906-B | Novel optical material composition containing mercaptan compound | 三菱瓦斯化学株式会社 | 2018-12-04 | — | — | CN | disclosed |
| CN-107531906-A | Novel optical material composition containing mercaptan compound | 三菱瓦斯化学株式会社 | 2018-01-02 | — | — | CN | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2015188197-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015069932-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-05-14 | — | — | WO | disclosed |
| US-7144954-B2 | Highly transparent plastic for optical materials | Röhm GmbH & Co. KG (DE) | 2006-12-05 | — | — | US | disclosed |
| US-20050261421-A1 | Highly transparent plastic for optical materials | ROEHM GMBH & CO. KG (DE) | 2005-11-24 | — | — | US | disclosed |
| EP-1558573-A1 | HIGHLY TRANSPARENT PLASTIC FOR OPTICAL MATERIALS | Röhm GmbH & Co. KG (DE) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004041775-A1 | HIGHLY TRANSPARENT PLASTIC FOR OPTICAL MATERIALS | Röhm GmbH & Co. KG (DE) | 2004-05-21 | — | — | WO | disclosed |
| US-5180735-A | Antitumor agents, angiogenesis inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-01-19 | — | — | US | disclosed |
| CN-1059723-A | Hete rocyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1992-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | IDO1 2829/4885APOBEC3G 234/4885PDCD1 2569/4885 |
| US-11090316-B2 | Lipid disulfide prodrugs and uses related thereto | SMPD1, SGMS1, SGMS2 | IDO1 2079/4885APOBEC3G 1761/4885PDCD1 2681/4885 |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | IDO1 2829/4885APOBEC3G 234/4885PDCD1 2569/4885 |
| US-20200306272-A1 | Lipid Disulfide Prodrugs and Uses Related Thereto | SMPD1, SGMS1, SGMS2 | IDO1 2079/4885APOBEC3G 1761/4885PDCD1 2681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.